Pfizer Inc. $PFE Shares Sold by BLB&B Advisors LLC

BLB&B Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 10.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 45,095 shares of the biopharmaceutical company’s stock after selling 5,319 shares during the quarter. BLB&B Advisors LLC’s holdings in Pfizer were worth $1,093,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter worth $27,000. Curio Wealth LLC grew its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the second quarter worth $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.0%

NYSE PFE opened at $24.30 on Friday. The firm’s 50-day moving average is $24.80 and its two-hundred day moving average is $24.25. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $28.64. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $138.15 billion, a P/E ratio of 12.93, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.